Evaluation effect disulfiram and valporat sodium in reactivation of HIV-1 latent viruses
- Conditions
- HIV AIDS.Human immunodeficiency virus [HIV]
- Registration Number
- IRCT201411304076N16
- Lead Sponsor
- Resaerch Deputy tehran university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 8
latent HIV-1 infected persons; confirm their sero positive infection by ELISA or WESTERN BLOT in last year; men, women age 40< x>18 years old; plasma HIV-1 RNA < 50 copies/ml for 1 year while on constant c ART; CD4 cell count = 500 cells/µl at screening; vital signs, physical test and clinical test be checked; CBC test and chemical test was checked; Hb>10 gr/dl, Plt count >105 /microlit, Creatinine clearance >50 gr/dl, Neu count >.75×109 cell/ml, Hepatic Trans aminase<2.5×ULN; Karnofsky performance status> 80%; DNA proviral prior to study 10Exclusion criteria: sero positive person for HBV / HPV/ HCV/ EBV/ GBV/ CMV/ opportunistic infection andUntreatedfungal infectious for at least 2 months; pregnant and foster women; person who under treatment of immunological drugs; person who wasn’t surviving for any kind of cancer since 5 years ago; person who has hyperaesthesia to immune vaccine and who has hyperaesthesia to immune disease like Hashimoto's thyroiditisand SLE; abuser of alcohol and drug; person who took cytotoxic drug and systemic Corticosteroid 4 weeks before study at least; untreated hypertension; person who has coagulating disorders; person who has Pancreatitis , liver and kidney 's disorders; person who has intense myocardial disease and Coronary artery; person who has psychosis; person who has taken Asprin/ Warfarin/ Phenobarbital/ Maraviroc/ Tipranavir/ Phenytoin/ Carbamazepine daily; person who has signs of MAC 2 months prior study; person who has allergy to VPA and DSF.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in DNA viral load. Timepoint: 14 days , 16 weeks. Method of measurement: blood sample.
- Secondary Outcome Measures
Name Time Method CD4 count. Timepoint: 17 Weeks. Method of measurement: blood sample.